TD Cowen analyst Charles Rhyee upgraded GoodRx to Outperform from Market Perform with a price target of $12, up from $6.50.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GDRX:
- GoodRx price target raised to $8 from $6 at Morgan Stanley
- GoodRx PBM partnerships can be ‘game changer,’ says TD Cowen
- GoodRx launch of program at CVS can boost active users, says KeyBanc
- CVS Health, GoodRx launch Caremark Cost Saver
- GoodRx appoints Dorothy Gemmell as Chief Commercial Officer, effective July 3